24/7 Market News Snapshot 10 March, 2025 – Mineralys Therapeutics, Inc. Common Stock (NASDAQ:MLYS)

March 10, 2025

DENVER, Colo., 10 March, 2025 (247marketnews.com) – (NASDAQ:MLYS) are discussed in this article.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has recently captured significant market attention, with its stock experiencing a remarkable rally. Opening at $14.13, shares have surged by over 45%, currently trading at $15.28, following a previous closing price of $10.52. This remarkable increase reflects strong investor sentiment and heightened trading activity, evidenced by a volume of 15.15 million shares. Market analysts are closely monitoring this momentum, anticipating its potential impact on the company’s trajectory as it continues to innovate in therapeutic solutions.

In a strategic move to bolster its clinical development efforts, Mineralys has announced a $250 million underwritten public offering of its common stock. The offering aims to provide the necessary capital to advance the development of lorundrostat, its leading candidate targeting hypertension and other aldosterone-related conditions. The company has also planned for an additional 30-day option for underwriters to purchase up to $37.5 million in shares, depending on market conditions. All shares in this offering are being sold directly by Mineralys, reflecting its commitment to maximizing shareholder value.

Proceeds from the public offering are earmarked for the continued clinical development of lorundrostat, covering research, development, manufacturing, marketing expenses, and general corporate needs. Mineralys is partnering with prominent financial institutions, including BofA Securities, Evercore ISI, and Goldman Sachs, as joint book-running managers for this offering, with LifeSci Capital and H.C. Wainwright & Co. also contributing to the management.

The company plans to file a preliminary prospectus with the Securities and Exchange Commission (SEC) related to this offering, which is being conducted under a previously effective shelf registration statement. Mineralys remains dedicated to addressing critical health challenges through innovative therapies, and this funding initiative is a crucial step towards achieving that goal.

Related news for (MLYS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.